Analysts Anticipate Novavax, Inc. (NVAX) Will Post Earnings of -$0.14 Per Share

Equities research analysts predict that Novavax, Inc. (NASDAQ:NVAX) will report earnings of ($0.14) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Novavax’s earnings, with estimates ranging from ($0.15) to ($0.13). Novavax reported earnings of ($0.16) per share during the same quarter last year, which would indicate a positive year over year growth rate of 12.5%. The firm is scheduled to issue its next quarterly earnings results on Monday, May 14th.

According to Zacks, analysts expect that Novavax will report full year earnings of ($0.54) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.42). For the next financial year, analysts forecast that the company will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.76) to ($0.34). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Novavax.

How to Become a New Pot Stock Millionaire

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The company had revenue of $10.40 million during the quarter, compared to the consensus estimate of $7.98 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. The company’s revenue was up 92.6% compared to the same quarter last year.

Several equities research analysts have recently issued reports on the company. B. Riley set a $10.00 price objective on Novavax and gave the company a “buy” rating in a research note on Thursday, January 11th. Ladenburg Thalmann Financial Services raised their price objective on Novavax to $2.50 and gave the company a “buy” rating in a research note on Thursday, January 11th. S&P Equity Research lowered their price objective on Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. BidaskClub raised Novavax from a “hold” rating to a “buy” rating in a research note on Thursday, March 15th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price objective on shares of Novavax in a research note on Thursday, March 15th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. Novavax currently has an average rating of “Hold” and a consensus target price of $3.11.

Several large investors have recently bought and sold shares of the company. MetLife Investment Advisors LLC bought a new stake in shares of Novavax in the 4th quarter valued at approximately $172,000. Teachers Advisors LLC raised its holdings in shares of Novavax by 17.2% in the fourth quarter. Teachers Advisors LLC now owns 583,645 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 85,611 shares during the period. California State Teachers Retirement System raised its holdings in shares of Novavax by 8.3% in the fourth quarter. California State Teachers Retirement System now owns 492,492 shares of the biopharmaceutical company’s stock worth $611,000 after buying an additional 37,793 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Novavax in the fourth quarter worth approximately $215,000. Finally, Deutsche Bank AG raised its holdings in shares of Novavax by 6.3% in the fourth quarter. Deutsche Bank AG now owns 2,567,169 shares of the biopharmaceutical company’s stock worth $3,182,000 after buying an additional 152,974 shares during the period. 39.22% of the stock is owned by institutional investors and hedge funds.

NVAX stock opened at $2.13 on Wednesday. Novavax has a one year low of $0.73 and a one year high of $2.75. The company has a market capitalization of $742.48, a P/E ratio of -3.38 and a beta of 2.50. The company has a debt-to-equity ratio of -3.12, a quick ratio of 2.76 and a current ratio of 2.76.

TRADEMARK VIOLATION WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2018/03/21/analysts-anticipate-novavax-inc-nvax-will-post-earnings-of-0-14-per-share.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Get a free copy of the Zacks research report on Novavax (NVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit